Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)

NCT ID: NCT02065401

Last Updated: 2021-06-02

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-28
• Study Completion Date: 2014-03-19

Brief Summary

The purpose of this study is to compare the pharmacokinetic profiles of deferitazole after administration of granule and tablet formulations of a deferitazole disodium salt to a capsule formulation of deferitazole magnesium hydroxide salt (reference formulation) in healthy adult subjects.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Deferitazole (disodium salt, granule)

Group Type: EXPERIMENTAL

Deferitazole (disodium salt, granule)

Intervention Type: DRUG

Single oral dose of 1500 mg administered on Day 1

Deferitazole (disodium salt, tablet)

Group Type: EXPERIMENTAL

Deferitazole (disodium salt, tablet)

Intervention Type: DRUG

Single oral dose of 1500 mg administered on Day 1

Deferitazole (magnesium hydroxide salt)

Group Type: EXPERIMENTAL

Deferitazole (magnesium hydroxide salt)

Intervention Type: DRUG

Single oral dose of 2400 mg administered on Day 1

Interventions

Deferitazole (disodium salt, granule)

Single oral dose of 1500 mg administered on Day 1

Intervention Type: DRUG

Deferitazole (disodium salt, tablet)

Single oral dose of 1500 mg administered on Day 1

Intervention Type: DRUG

Deferitazole (magnesium hydroxide salt)

Single oral dose of 2400 mg administered on Day 1

Intervention Type: DRUG

Other Intervention Names

SPD602, SSP-004184, SSP-004184SS; SPD602, SSP-004184, SSP-004184SS; SPD602, SSP-004184AQ, SSP-004184

Eligibility Criteria

Inclusion Criteria

1. Age 18-65 years inclusive at the time of consent.

2. Must be considered "healthy".

3. Serum ferritin, hemoglobin and erythrocyte indices (packed cell volume, mean corpuscular volume and mean corpuscular hemoglobin concentration) within normal range.

4. Willingness to comply with any applicable contraceptive requirements of the protocol and is:

• Male, or
• Female of non-childbearing potential (defined as a female who is post-menopausal )
• Non-pregnant, non-lactating female
• Females must be at least 90 days post partum or nulliparous.

5. Body weight equal to or greater than 60kg.

6. Ability to swallow a dose of the investigational product.

Exclusion Criteria

1. Subject has a clinically significant history or a disorder detected during the medical interview/physical examination.

2. Acute illness.

3. Oral condition:

• Has history of oral surgery (including extractions) within 4 weeks, operative dental work within 7 days, or a presence of any clinically significant oral pathology (as determined by the investigator) including lesions, sores or inflammation which would interfere with assessments.
• Has fixed retainers, orthodontic appliances, or either maxillary and/or mandibular dentures or other appliances which may interfere with swilling or tasting the formulations.
• Has current or recurrent disease that could affect the mouth and interfere with the taste assessment.
• Has severe gingivitis, periodontitis or rampant caries.
• Has the presence of oral or peri-oral ulceration including herpetic lesions
• Has elective dentistry scheduled during the study duration.

4. Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment.

5. History of alcohol or other substance abuse within the year.

6. A positive screen for alcohol or drugs of abuse.

7. Confirmed systolic blood pressure >139mmHg or <89mmHg, and diastolic blood pressure >89mmHg or<49mmHg.

8. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches.

9. Male subjects who consume more than 3 units of alcohol per day. Female subjects who consume more than 2 units of alcohol per day.

10. A positive human immunodeficiency virus antibody screen, hepatitis B surface antigen, or hepatitis C virus antibody.

11. Current use of any other medication (including over-the-counter, herbal, or homeopathic preparations)

12. Current use of iron supplements and/or multivitamins.

13. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products.

14. Donation of blood or blood products (e.g., plasma or platelets) within 60 days.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Shire

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

Clinical Pharmacology of Miami

Miami, Florida, United States

Countries

United States

Other Identifiers

SPD602-112

Identifier Type: -

Identifier Source: org_study_id